Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

  • Unknown sort schema '{last_sort_schema}' ignored
  • The following term was not found in PubMed: F%5BAuthor%5D.
1.

Should aspirin and PPIs be recommended for patients with Barrett's oesophagus?

Hvid-Jensen F, Drewes AM.

Lancet. 2018 Aug 4;392(10145):362-364. doi: 10.1016/S0140-6736(18)31618-0. Epub 2018 Jul 26. No abstract available.

2.

Pulmonary hemorrhage following anabolic agent abuse: Two cases.

Hvid-Jensen HS, Rasmussen F, Bendstrup E.

Respir Med Case Rep. 2016 Apr 13;18:45-7. doi: 10.1016/j.rmcr.2016.04.001. eCollection 2016.

3.
4.

Barrett's oesophagus: size does matter.

de Jonge PJ, Hvid-Jensen F.

Gut. 2016 Feb;65(2):189-90. doi: 10.1136/gutjnl-2015-310091. Epub 2015 Aug 5. No abstract available.

PMID:
26246246
5.

Benign and precursor lesions in the esophagus.

Akiyama J, Bertelé A, Brock C, Hvid-Jensen F, Ichiya T, Krarup AL, Majewski M, Rubio CA, Sarosiek J, Scarpignato C, Schmidt PT, Teich S, Triadafilopoulos G, Wallner G.

Ann N Y Acad Sci. 2014 Sep;1325:226-41. doi: 10.1111/nyas.12534.

PMID:
25266028
6.

Letter: proton pump inhibitor usage still seems to reduce the risk of high-grade dysplasia and/or oesophageal adenocarcinoma in Barrett's oesophagus--authors' reply.

Hvid-Jensen F, Drewes AM, Funch-Jensen P.

Aliment Pharmacol Ther. 2014 Oct;40(7):860-1. doi: 10.1111/apt.12931. No abstract available.

7.

Letter: proton pump inhibitors, GERD and oesophageal adenocarcinoma - authors' reply.

Hvid-Jensen F, Funch-Jensen P, Drewes AM.

Aliment Pharmacol Ther. 2014 Aug;40(3):320. doi: 10.1111/apt.12847. No abstract available.

8.

Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients.

Hvid-Jensen F, Pedersen L, Funch-Jensen P, Drewes AM.

Aliment Pharmacol Ther. 2014 May;39(9):984-91. doi: 10.1111/apt.12693. Epub 2014 Mar 11.

9.

Lifestyle factors among proton pump inhibitor users and nonusers: a cross-sectional study in a population-based setting.

Hvid-Jensen F, Nielsen RB, Pedersen L, Funch-Jensen P, Drewes AM, Larsen FB, Thomsen RW.

Clin Epidemiol. 2013 Dec 4;5:493-9. doi: 10.2147/CLEP.S49354. eCollection 2013.

10.

Randomized clinical trial: inhibition of the TRPV1 system in patients with nonerosive gastroesophageal reflux disease and a partial response to PPI treatment is not associated with analgesia to esophageal experimental pain.

Krarup AL, Ny L, Gunnarsson J, Hvid-Jensen F, Zetterstrand S, Simrén M, Funch-Jensen P, Hansen MB, Drewes AM.

Scand J Gastroenterol. 2013 Mar;48(3):274-84. doi: 10.3109/00365521.2012.758769. Epub 2013 Jan 16.

PMID:
23320520
11.

Incidence of adenocarcinoma among patients with Barrett's esophagus.

Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P.

N Engl J Med. 2011 Oct 13;365(15):1375-83. doi: 10.1056/NEJMoa1103042.

12.

Long-term complications to reflux disease in community practice. A 17-year cohort study of 4706 patients.

Hvid-Jensen F, Pedersen L, Munk EM, Drewes AM, Funch-Jensen P.

Scand J Gastroenterol. 2011 Oct;46(10):1179-86. doi: 10.3109/00365521.2011.594084. Epub 2011 Jul 27.

PMID:
21793632
13.

Randomised clinical trial: the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain.

Krarup AL, Ny L, Astrand M, Bajor A, Hvid-Jensen F, Hansen MB, Simrén M, Funch-Jensen P, Drewes AM.

Aliment Pharmacol Ther. 2011 May;33(10):1113-22. doi: 10.1111/j.1365-2036.2011.04629.x. Epub 2011 Mar 16.

14.

The esophageal multimodal pain model: normal values and degree of sensitization in healthy young male volunteers.

Krarup AL, Simrén M, Funch-Jensen P, Hansen MB, Hvid-Jensen F, Brun J, Drewes AM.

Dig Dis Sci. 2011 Jul;56(7):1967-75. doi: 10.1007/s10620-010-1546-1. Epub 2011 Jan 8.

PMID:
21221787

Supplemental Content

Loading ...
Support Center